Underlying athenahealth business strengthening, says Sterne Agee


After athenahealth provided weaker than expected FY14 guidance, Sterne Agee expects the company's revenue growth to rebound to 30% as its enterprise accounts are implemented and ramp to optimal levels. The firm keeps a $179 price target and Buy rating on the shares.

View Comments (0)